Rasagiline
Rasagiline is a once-daily tablet medicine that treats Parkinson’s disease, either on its own or added to other Parkinson’s treatment.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 18 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Rasagiline (Azilect) is a once-daily Parkinson’s disease medicine that blocks MAO-B, an enzyme that breaks down dopamine, and it is a well-established, fairly gentle option used alone early on or added to levodopa, on the market since about 2006 and available as a generic. Most people tolerate it well, with headache, joint aches, indigestion and dizziness as the usual complaints, and alongside levodopa it can bring more uncontrolled movements (dyskinesia). The real thing to watch is interactions, because dextromethorphan cough medicines, tramadol, meperidine, methadone and many antidepressants can trigger dangerous reactions, so run every new medicine past your pharmacist first, including cold remedies and herbal products.
Clinical pearls
- Avoid very aged cheeses like Stilton and other tyramine-heavy foods, but a strict MAOI diet is not needed at usual doses.
- Decongestant tablets, nasal sprays and even redness-relief eye drops can push blood pressure up, so choose cold remedies carefully.
- Sudden sleep episodes during daily activities, including driving, have been reported, so report any unexpected dozing off promptly.
- Melanoma has been reported in people taking rasagiline, so get any new or changing mole looked at.
Patient information guide A plain-language walkthrough of Rasagiline, written from its FDA label.
What Rasagiline is used for
▾
Rasagiline is used for one condition across all its tablet products.
- Parkinson’s disease: Azilect tablets, rasagiline tablets, and rasagiline mesylate tablets are all taken by mouth for this use.
- It can be used alone or added to other Parkinson’s medicines, including levodopa.
How Rasagiline works
▾
Rasagiline is a selective, irreversible blocker of MAO-B, an enzyme that breaks down dopamine in the brain. Blocking it is believed to raise dopamine levels in the striatum, a movement-control area. This is likely behind its benefit for movement problems in Parkinson’s disease. The exact mechanism is not fully known.
At recommended doses it mainly targets MAO-B. That selectivity fades as the dose goes above the recommended amount.
Rasagiline dosage
▾
Rasagiline is taken by mouth as a tablet once a day, with or without food.
- Your starting dose depends on whether you also take levodopa.
- People taking ciprofloxacin or other CYP1A2 inhibitors, or with mild liver impairment, are kept on a lower maximum dose.
- If you take it with levodopa, your doctor may lower the levodopa dose.
Follow your prescriber and the label, and do not exceed the recommended dose because of the risk of high blood pressure.
Dosing details from the FDA-approved label
From the Rasagiline prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Monotherapy
- 1 mg administered orally once daily
- Maximum: The recommended doses should not be exceeded because of risk of hypertension
- Adjunct therapy in patients not taking levodopa
- 1 mg administered orally once daily
- Maximum: The recommended doses should not be exceeded because of risk of hypertension
- Adjunct to levodopa (with or without other PD drugs)
- Initial dose 0.5 mg once daily
- If the 0.5 mg dose is tolerated but a sufficient clinical response is not achieved, the dose may be increased to 1 mg once daily
- Maximum: 1 mg once daily
- A reduction of the levodopa dose may be considered, based upon individual response
- Patients taking ciprofloxacin or other CYP1A2 inhibitors
- 0.5 mg once daily
- Maximum: Should not exceed 0.5 mg once daily
- Mild hepatic impairment
- 0.5 mg once daily
- Maximum: Should not exceed 0.5 mg once daily
- Should not be used in patients with moderate or severe hepatic impairment
Read the label’s full dosing text
2 DOSAGE & ADMINISTRATION • Monotherapy: Rasagiline tablets 1 mg once daily ( 2.1 ) • As adjunct without levodopa: Rasagiline tablets 1 mg once daily (2.1) • As adjunct to levodopa: Rasagiline tablets 0.5 mg once daily. Increase dose to 1 mg daily as needed for sufficient clinical response ( 2.1 ) • Patients taking ciprofloxacin or other CYP1A2 inhibitors: Rasagiline tablets 0.5 mg once daily ( 2.2 , 5.4 ) • Patients with mild hepatic impairment: Rasagiline tablets 0.5 mg once daily. Rasagiline tablets should not be used in patients with moderate or severe hepatic impairment ( 2.3 , 5.5 ) 2.1 General Dosing Recommendations When rasagiline tablets are prescribed as monotherapy or as adjunct therapy in patients not taking levodopa, patients may start rasagiline tablets at the recommended dose of 1 mg administered orally once daily. In patients taking levodopa, with or without other PD drugs (e.g., dopamine agonist, amantadine, anticholinergics) the recommended initial dose of rasagiline tablets is 0.5 mg once daily. If the patient tolerates the daily 0.5 mg dose, but a sufficient clinical response is not achieved, the dose may be increased to 1 mg once daily. When rasagiline tablets are used in combination with levodopa, a reduction of the levodopa dose may be considered, based upon individual response. The recommended doses of rasagiline tablets should not be exceeded because of risk of hypertension [see Warnings and Precautions ( 5.1 )]. 2.2 Patients Taking Ciprofloxacin or Other CYP1A2 Inhibitors Patients taking concomitant ciprofloxacin or other CYP1A2 inhibitors should not exceed a dose of rasagiline tablets 0.5 mg once daily [see Warnings and Precautions ( 5.4 ), Drug Interactions ( 7.6 ), and Clinical Pharmacology ( 12.3 ]. 2.3 Patients with Hepatic Impairment Patients with mild hepatic impairment should not exceed a dose of rasagiline tablets 0.5 mg once daily. Rasagiline tablets should not be used in patients with moderate or severe hepatic impairment [see Warnings and Precautions ( 5.5 ), Use in Specific Populations ( 8.6 ), and Clinical Pharmacology ( 12.3 )].
Read the full Dosage and Administration section on DailyMed →
Rasagiline side effects
▾
Side effects vary depending on whether rasagiline is used alone or with other medicines.
Common side effects
- Headache
- Joint pain (arthralgia)
- Indigestion (dyspepsia)
- Nausea
- Falls
- Dyskinesia (uncontrolled movements) when taken with levodopa
- Weight loss and dry mouth when taken with levodopa
- Dizziness
- Nausea and vomiting
- Weight loss, dry mouth, constipation, and low blood pressure on standing with levodopa
When to get medical help
- Call your doctor if you have a sustained rise in blood pressure or a severe headache, especially after eating high-tyramine foods.
- Get urgent help for symptoms of serotonin syndrome: confusion, agitation, high fever, sweating, shivering, fast heartbeat, muscle stiffness or twitching.
- Tell your doctor right away if you fall asleep during daily activities or have significant daytime sleepiness.
- Report hallucinations, paranoia, confusion, or new aggressive or unusual behavior promptly.
- Tell your doctor about new urges or compulsive behaviors.
- Report lightheadedness or fainting when standing up.
- Report new or worsening uncontrolled movements (dyskinesia).
- Call your doctor about any skin changes, as melanoma has been reported after approval.
Rasagiline warnings and precautions
▾
- High blood pressure: it can occur at recommended doses. Avoid foods with very large amounts of tyramine, such as aged cheeses.
- Serotonin syndrome: a potentially life-threatening reaction with certain antidepressants and pain medicines.
- Sleepiness: some people fall asleep suddenly during daily activities, including driving.
- Low blood pressure on standing: most common in the first two months.
- Mental changes: hallucinations, psychotic-like behavior, and impulse control problems can occur.
- Dyskinesia: it may worsen when used with levodopa.
- Stopping: withdrawal can cause high fever and confusion.
Rasagiline interactions
▾
Several medicines and foods can clash with rasagiline.
- Meperidine, tramadol, methadone, propoxyphene: serotonin syndrome risk. Contraindicated.
- Other MAO inhibitors: risk of hypertensive crisis. Contraindicated.
- Dextromethorphan: risk of psychosis or bizarre behavior. Contraindicated.
- St. John’s wort and cyclobenzaprine: contraindicated.
- Antidepressants: not recommended because of serotonin syndrome risk.
- Ciprofloxacin and other CYP1A2 inhibitors: raise rasagiline levels.
- Decongestants and cold remedies: may raise blood pressure.
- Antipsychotics and metoclopramide: may reduce rasagiline’s effectiveness.
- Very high tyramine foods: can cause severe blood pressure rise.
Interactions listed in the FDA-approved label
From the Rasagiline prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Meperidine: Serious, sometimes fatal reactions have been precipitated with concomitant use of meperidine and MAO inhibitors including selective MAO-B inhibitors (risk of serotonin syndrome). Contraindicated
- Dextromethorphan: The combination of MAO inhibitors and dextromethorphan has been reported to cause brief episodes of psychosis or bizarre behavior. Contraindicated for use with rasagiline tablets
- MAO inhibitors: Increased risk of nonselective MAO inhibition that may lead to a hypertensive crisis. Contraindicated for use with other MAO inhibitors
- Sympathomimetic medications (including nasal, oral, and ophthalmic decongestants and cold remedies): Hypertensive crisis and severe hypertension have been reported in patients taking the recommended dose of rasagiline tablets with sympathomimetic medications, including ophthalmic drops containing them. Caution should be exercised when concomitantly using recommended doses of rasagiline tablets with any sympathomimetic medications
- Antidepressants (e.g., SSRIs, SNRIs, triazolopyridine, tricyclic or tetracyclic antidepressants): Concomitant use with one of many classes of antidepressants. Concomitant use is not recommended
- Ciprofloxacin or other CYP1A2 inhibitors: Rasagiline plasma concentrations may increase up to 2 fold, which could result in increased adverse events. Should not exceed a dose of rasagiline tablets 0.5 mg once daily
- Tyramine-containing foods and medications: Rasagiline is selective for MAO-B at recommended doses and can be used without dietary tyramine restriction, but certain foods with very high amounts (150 mg or greater) of tyramine could potentially cause a hypertensive reaction; postmarketing reports of significantly elevated blood pressure after tyramine-rich foods. Patients should be advised to avoid foods containing a very large amount of tyramine while taking recommended doses
- Dopaminergic antagonists (e.g., antipsychotics, metoclopramide): Could diminish the effectiveness of rasagiline tablets.
Read the label’s full interactions text
7 DRUG INTERACTIONS • Meperidine: Risk of serotonin syndrome ( 4 , 7.1 ) • Dextromethorphan: Risk of psychosis or bizarre behavior ( 4 , 7.2 ) • MAO inhibitors: Risk of non-selective MAO inhibition and hypertensive crisis ( 4 , 7.3 ) 7.1 Meperidine Serious, sometimes fatal reactions have been precipitated with concomitant use of meperidine (e.g., Demerol and other tradenames) and MAO inhibitors including selective MAO-B inhibitors [see Contraindications ( 4 )]. 7.2 Dextromethorphan The concomitant use of rasagiline tablets and dextromethorphan was not allowed in clinical studies. The combination of MAO inhibitors and dextromethorphan has been reported to cause brief episodes of psychosis or bizarre behavior. Therefore, in view of rasagiline's MAO inhibitory activity, dextromethorphan is contraindicated for use with rasagiline tablets [see Contraindications ( 4 )]. 7.3 MAO Inhibitors Rasagiline tablets are contraindicated for use with other MAO inhibitors because of the increased risk of nonselective MAO inhibition that may lead to a hypertensive crisis [see Contraindications ( 4 ) ]. 7.4 Sympathomimetic Medications The concomitant use of rasagiline tablets and sympathomimetic medications was not allowed in clinical studies. Severe hypertensive reactions have followed the administration of sympathomimetics and nonselective MAO inhibitors. Hypertensive crisis has been reported in patients taking the recommended dose of rasagiline tablets and sympathomimetic medications. Severe hypertension has been reported in patients taking the recommended dose of rasagiline tablets and ophthalmic drops containing sympathomimetic medications. Because rasagiline tablets are a selective MAOI, hypertensive reactions are not ordinarily expected with the concomitant use of sympathomimetic medications.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Rasagiline
▾
- Do not use with the contraindicated medicines listed above. At least 14 days should pass after stopping rasagiline before starting some of these medicines.
- Mild liver impairment needs a lower maximum dose. It should not be used with moderate or severe liver impairment.
- No dose change is needed for mild or moderate kidney impairment.
- Pregnancy: animal data suggest possible harm, and there are no adequate human data.
- Breastfeeding: no data on milk transfer, so talk with your doctor.
- Not studied in children under 18.
- Older adults had no significant safety differences in trials.
Rasagiline overdose
▾
Overdose with MAO inhibitors can cause serious effects such as severe headache, agitation, hallucinations, convulsions, blood pressure changes, and high fever. Symptoms may be delayed by up to 12 hours. There is no specific antidote, so call a poison control center and seek emergency care right away.
What Rasagiline does in the body
▾
At recommended doses, rasagiline mainly blocks MAO-B and can be used without routine tyramine restriction. Its effect on MAO-B is irreversible and lasts at least a week after the last dose. Selectivity decreases as the dose rises above the highest recommended amount.
How your body processes Rasagiline
▾
Rasagiline is absorbed quickly, peaking in about an hour, and can be taken with or without food. It is broken down almost entirely in the liver, mainly by the CYP1A2 enzyme. Its half-life is about 3 hours, but its effect lasts much longer because it irreversibly blocks MAO-B. Most of it leaves the body through urine.
How to store Rasagiline
▾
Rasagiline 0. Store at 25°C (77°F) with excursions permitted to 15° to 30°C (59° to 86°F).
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Rasagiline
173 supplements and herbal products have documented interactions with Rasagiline in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 14
- Moderate · 125
- Minor · 34
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Rasagiline: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Rasagiline — the kind of thing our pharmacy team would talk through with you at the counter.
What is rasagiline for?
▾
How do I take it?
▾
Do I need to avoid certain foods?
▾
What medicines should I check before taking with rasagiline?
▾
What side effects should I watch for?
▾
Is it safe in pregnancy?
▾
Is Rasagiline available over the counter?
▾
When was Rasagiline first available?
▾
Who makes Rasagiline?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Rasagiline on HelloPharmacist
Rasagiline forms and strengths (how it comes)
Rasagiline is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Azilect tablets are used to treat Parkinson’s disease.
- Rasagiline tablets and rasagiline mesylate tablets are used to treat Parkinson’s disease.
- Azilect is taken by mouth once daily, as monotherapy or as an add-on to other Parkinson’s treatment.
- Rasagiline tablets are taken by mouth once daily, and the starting dose depends on whether levodopa is also used.
- Rasagiline mesylate tablets are taken by mouth once daily, and doses are limited with ciprofloxacin or mild liver impairment.
- Rasagiline tablets can be taken with or without food.
Rasagiline on the U.S. market: products, makers and brands
How Rasagiline appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
16 companies list 31 Rasagiline product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2006. Brand names on the directory include Azilect; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (10) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Rasagiline is used (Medicaid data)
A general measure of how commonly Rasagiline is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Rasagiline is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Rasagiline prescribed? Of the 1,601 medications we measure, Rasagiline ranks #1,253 by Medicaid prescriptions — more than 22% of them.
Utilization by Rasagiline product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
rasagiline 1 MG Oral Tablet Most dispensed
Summed across the 6 of 28 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 608328
rasagiline 0.5 MG Oral Tablet
Summed across the 3 of 27 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 636664
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Rasagiline, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 9 of 55 listed Rasagiline NDCs with Medicaid activity.
Compare Rasagiline products
A representative set of FDA-listed product records for Rasagiline — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 0.5 mg | Oral | Alvogen, Inc. | ANDA | View NDC → |
| 1 mg | Oral | Alvogen, Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 1 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 1 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 0.5 mg | Oral | Carnegie Pharmaceuticals LLC | ANDA | View NDC → |
| 1 mg | Oral | Carnegie Pharmaceuticals LLC | ANDA | View NDC → |
| 0.5 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 1 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 0.5 mg | Oral | Florida Pharmaceutical Products, LLC | ANDA | View NDC → |
| 1 mg | Oral | Florida Pharmaceutical Products, LLC | ANDA | View NDC → |
| 0.5 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 1 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 1 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 0.5 mg | Oral | Micro Labs Limited | ANDA | View NDC → |
| 1 mg | Oral | Micro Labs Limited | ANDA | View NDC → |
| 0.5 mg | Oral | NorthStar RxLLC | ANDA | View NDC → |
| 1 mg | Oral | NorthStar RxLLC | ANDA | View NDC → |
| 0.5 mg | Oral | Remedyrepack Inc. | ANDA | View NDC → |
| 1 mg | Oral | Remedyrepack Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 1 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | SKG Pharma Inc. | ANDA | View NDC → |
| 1 mg | Oral | SKG Pharma Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | Teva Neuroscience, Inc. | NDA | View NDC → |
| 1 mg | Oral | Teva Neuroscience, Inc. | NDA | View NDC → |
| 0.5 mg | Oral | Teva Pharmaceuticals USA, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 1 mg | Oral | Teva Pharmaceuticals USA, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 0.5 mg | Oral | Torrent Pharmaceuticals Limited | ANDA | View NDC → |
| 1 mg | Oral | Torrent Pharmaceuticals Limited | ANDA | View NDC → |
Showing 31 of 31 products — FDA National Drug Code Directory. See every product, package size and price: browse all 31 Rasagiline NDCs →
Rasagiline side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Rasagiline — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Rasagiline in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Rasagiline FDA approval history
How Rasagiline went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Rasagiline recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list one Rasagiline recall since July 2021. It is no longer listed as ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Rasagiline Mesylate Tablets 1 mg; 30 tablets in HDPE bottle; Rx only; NDC 67877-260-30; Manufactured by Alkem Laboratories Ltd., India; Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054 Lots: Lot # 22140903. Exp. Dec. 2024 FDA record D-0159-2023 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 134748 1 dose form · 2 strengths
-
Dose form (SCDF) Oral Tablet RxCUI 608327In current FDA listings
Look up RxCUI 134748 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Rasagiline supply and shortage status
Whether Rasagiline is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Rasagiline costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet · Oral | 1 mg | $0.926 per tablet | NDC details & price history |
| Tablet · Oral | 0.5 mg | $0.521 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Rasagiline brand names
Rasagiline is sold under one brand name in the FDA directory — Azilect. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Rasagiline: manufacturers and labelers
16 companies list Rasagiline products with the FDA. By number of product records, the largest are Alvogen, Inc., Ascend Laboratories, LLC, Carnegie Pharmaceuticals LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Rasagiline drug class (RxNorm)
Rasagiline belongs to the Monoamine Oxidase Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Rasagiline page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Teva Pharmaceuticals USA, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →